Uses of Almitan 6.25 mg: - Migraine Oral Acute migraine attacks Adult: Initially, 6.25-12.5 mg. May repeat 2 hr later if needed. Max: 2 doses/24 hr. Hepatic Impairment Initially, 6.25 mg as a single dose. Max: 12.5 mg/24 hr. Avoid in severe impairment. Oral Child: Migraine Indicated for acute treatment of migraine headache pain in adolescents with a history of migraine attacks with or without aura usually lasting >4 hr (when untreated) <12 years: Safety and efficacy not established >12 years: 6.25-12.5 mg PO at onset of headache; may repeat once after 2 hr Not to exceed 25 mg/day

5-HT Agonists

Almotriptan is a selective and potent serotonin (5-hydroxytryptamine 1B/1D) agonist. Almotriptan binds to specific serotonin receptors on meningeal arteries inhibiting the release of vasoactive peptides and causing constriction of the arteries. It has a limited effect on arteries supplying blood to the brain and little effect on cardiac and pulmonary vessels.

How to use Almotriptan: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Almotriptan may be taken with or without food, but it is better to take it at a fixed time. Administration: Increased risk of serotonin syndrome when used with SSRIs or serotonin norepinephrine reuptake inhibitors. Increased plasma concentrations when used with verapamil, ketoconazole or other potent CYP450 inhibitors. Potentially Fatal: Severe vasospastic reactions may occur when given within 24 hr of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-like medication. Avoid usage with or within 2 wk of stopping treatment with a MAOI. Adult Dose: Hypersensitivity to sulfonamides. Hepatic or moderate-severe renal impairment. Caution when used in patients with a history of seizures. May significantly increase BP. May cause drowsiness. Children <18 yr. Pregnancy, lactation. Lactation: excretion in milk unknown; use with caution Renal Dose: Almotriptan is a selective serotonin agonist which acts mainly on the 5-HT1 receptors and produces cranial vasodilation. It is used for the acute treatment of migraine.

Underlying CV disease e.g. ischaemic heart disease or coronary artery vasospasm. Uncontrolled hypertension. Severe hepatic or renal impairment. Prophylaxis of migraine, hemiplegic or basilar migraine; cluster headache. Use within 24 hr of another 5-HT1 agonist; use within 24 hr of ergotamine derivative; concurrent use or within 2 wk of discontinuing an MAOI.

Oral Child: Migraine Indicated for acute treatment of migraine headache pain in adolescents with a history of migraine attacks with or without aura usually lasting >4 hr (when untreated) <12 years: Safety and efficacy not established >12 years: 6.25-12.5 mg PO at onset of headache; may repeat once after 2 hr Not to exceed 25 mg/day

Common - Dizziness - Dryness in mouth - Flushing (sense of warmth in the face, ears, neck and trunk) - Jaw pain - Nausea - Neck pain - Sleepiness - Throat pain - Weakness Renal Impairment Initially, 6.25 mg as a single dose. Max: 12.5 mg/24 hr.

Pregnancy Category C. There is no data regarding excretion of almotriptan in human milk.

Precaution: Migraine headache, Acute migraine attacks

Keep below 30° C temperature in a dry place. Protected from light. Do not freeze. Keep out of the reach of children.

5-HT Agonists

May be taken with or without food.

1-10% Somnolence (1-5%),Dizziness (3-4%),Nausea (1-3%),Vomiting (2%),Dry mouth (1-2%),Headache (1-2%),Nausea (1-2%),Paresthesia (1-2%),Paresthesia (1%),Somnolence (>1%) <1% Infrequent (0.01-0.001%) Anxiety, asthenia, chills, CNS stimulation, fatigue, hypesthesia, tremor, Pruitus, rash, Diaphoresis, dysmenorrhea, hyperglycemia, increased thirst, Abdominal cramp, gastroenteritis Back pain, myalgia, neck pain, rigid neck, Increased CPK, Bronchitis, chest pain, dyspnea, pharyngitis, rhinitis, sinusitis, Conjunctivitis, tinnitis, vertigo Potentially Fatal: Serious cardiac events.